Standout Papers

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and U... 2015 2026 2018 2022 634
  1. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials (2015)
    C.E.M. Griffiths, Kristian Reich et al. The Lancet
  2. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis (2016)
    Kenneth B. Gordon, Andrew Blauvelt et al. New England Journal of Medicine

Immediate Impact

5 by Nobel laureates 7 from Science/Nature 67 standout
Sub-graph 1 of 20

Citing Papers

Active biointegrated living electronics for managing inflammation
2024 StandoutScience
TH17 cell heterogeneity and its role in tissue inflammation
2023 Standout
1 intermediate paper

Works of Roberta J. Secrest being referenced

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
2015 Standout

Author Peers

Author Last Decade Papers Cites
Roberta J. Secrest 512 83 485 1170 708 27 2.5k
Keith S. Kanik 452 59 760 1754 342 50 4.9k
Pawel Zerr 240 105 286 656 476 39 3.4k
Steven Ledbetter 629 80 557 617 117 56 4.0k
Robert J. Padley 137 152 534 213 83 64 3.8k
Albert S. Yu 61 51 395 609 75 48 3.1k
Siqun L. Zheng 1181 27 405 534 89 79 3.8k
Sarfaraz Hasni 223 59 479 1531 98 66 3.2k
Stefan Jenisch 146 29 218 1576 653 33 1.9k
Caitriona Ryan 170 77 244 2122 1296 54 3.0k
Céline C. Berthier 281 144 261 1835 193 65 3.5k

All Works

Loading papers...

Rankless by CCL
2026